Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.44 |
| ▸ | ITGAV | P06756 | 4/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534602 | 0.94 | ELANE (0.53) | ELANEITGB1ITGA4L3MBTL1KMT2A | |
| SCHEMBL4534596 | 0.94 | ELANE (0.53) | ELANEITGB1ITGA4L3MBTL1KMT2A | |
| SCHEMBL4521889 | 0.91 | ALDH1A1 (0.51) | ELANEITGB1ITGA4KMT2AMEN1 | |
| SCHEMBL4521881 | 0.91 | ALDH1A1 (0.51) | ELANEITGB1ITGA4KMT2AMEN1 | |
| SCHEMBL23461456 | 0.88 | CXCR2 (0.51) | ELANEITGB1ITGA4KMT2AMEN1 | |
| SCHEMBL23461455 | 0.88 | CXCR2 (0.51) | ELANEITGB1ITGA4KMT2AMEN1 | |
| SCHEMBL4523472 | 0.85 | CXCR2 (0.56) | ELANEITGB1ITGA4KMT2AMEN1 | |
| SCHEMBL4523475 | 0.85 | CXCR2 (0.56) | ELANEITGB1ITGA4KMT2AMEN1 | |
| SCHEMBL25548856 | 0.83 | ELANE (0.55) | ELANEKMT2AMEN1PPARGCXCR2 | |
| SCHEMBL4522750 | 0.82 | CXCR2 (0.57) | ELANEITGB1ITGA4ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | ELANE 49/4885ITGB1 4082/4885ITGA4 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.